First-in-human imaging and kinetic analysis of vesicular acetylcholine transporter density in the heart using [18F]FEOBV PET

In contrast to cardiac sympathetic activity which can be assessed with established PET tracers, there are currently no suitable radioligands to measure cardiac parasympathetic (cholinergic) activity. A radioligand able to measure cardiac cholinergic activity would be an invaluable clinical and resea...

Full description

Saved in:

Bibliographic Details
Published in:	Journal of nuclear cardiology 2021-02, Vol.28 (1), p.50-54
Main Authors:	Saint-Georges, Zacharie, Zayed, Vanessa K., Dinelle, Katie, Cassidy, Clifford, Soucy, Jean-Paul, Massarweh, Gassan, Rotstein, Benjamin, Nery, Pablo B., Guimond, Synthia, deKemp, Robert, Tuominen, Lauri
Format:	Article
Language:	eng
Subjects:	Adult Brief Report Cardiology Female Heart Heart - diagnostic imaging Humans Imaging innervation tracers Male Medicine Medicine & Public Health Middle Aged molecular imaging molecular imaging agents Myocardium - metabolism Nuclear Medicine PET Piperidines - pharmacokinetics Positron-Emission Tomography Radiology Reference Values Tracer development Vesicular Acetylcholine Transport Proteins - metabolism
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	In contrast to cardiac sympathetic activity which can be assessed with established PET tracers, there are currently no suitable radioligands to measure cardiac parasympathetic (cholinergic) activity. A radioligand able to measure cardiac cholinergic activity would be an invaluable clinical and research tool since cholinergic dysfunction has been associated with a wide array of pathologies (e.g., chronic heart failure, myocardial infarction, arrythmias). [18F]Fluoroethoxybenzovesamicol (FEOBV) is a cholinergic radiotracer that has been extensively validated in the brain. Whether FEOBV PET can be used to assess cholinergic activity in the heart is not known. Hence, this study aimed to evaluate the properties of FEOBV for cardiac PET imaging and cholinergic activity mapping. PET data were collected for 40 minutes after injection of 230 ± 50 MBq of FEOBV in four healthy participants (1 female; Age: 37 ± 10; BMI: 25 ± 2). Dynamic LV time activity curves were fitted with Logan graphical, 1-tissue compartment, and 2-tissue compartment models, yielding similar distribution volume estimates for each participant. Our initial data show that FEOBV PET has favorable tracer kinetics for quantification of cholinergic activity and is a promising new method for assessing parasympathetic function in the heart.
ISSN:	1071-3581 1532-6551